BRPI0715975A2 - Fragmento imunogênico de pcpa, composição,recipiente, métodos de gerar anticorpos específicos para pcpa em um indivíduo, de prevenir ou reduzir portador nasal pneumocócico em um indivíduo, e de reduzir o risco de uma infecção pneumocócica em um indivíduo, e, polipeptídeo isolado - Google Patents

Fragmento imunogênico de pcpa, composição,recipiente, métodos de gerar anticorpos específicos para pcpa em um indivíduo, de prevenir ou reduzir portador nasal pneumocócico em um indivíduo, e de reduzir o risco de uma infecção pneumocócica em um indivíduo, e, polipeptídeo isolado

Info

Publication number: BRPI0715975A2
Authority: BR; Brazil
Prior art keywords: reducing; pcpa; poceus; infocium; immunographic
Prior art date: 2006-08-17

Application number

BRPI0715975-7A2A

Other languages

English (en)

Inventor

David E Briles

Susan K Hollingshead

Jeremy Yethon

Joe Wang

Original Assignee

Uab Res Foudation

Sanofi Pasteur Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-17

Filing date

2007-08-17

Publication date

2014-03-18

2007-08-17 Application filed by Uab Res Foudation, Sanofi Pasteur Ltd filed Critical Uab Res Foudation

2014-03-18 Publication of BRPI0715975A2 publication Critical patent/BRPI0715975A2/pt

Links

NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical group OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 title 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56944—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Virology (AREA)
Oncology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)

BRPI0715975-7A2A 2006-08-17 2007-08-17 Fragmento imunogênico de pcpa, composição,recipiente, métodos de gerar anticorpos específicos para pcpa em um indivíduo, de prevenir ou reduzir portador nasal pneumocócico em um indivíduo, e de reduzir o risco de uma infecção pneumocócica em um indivíduo, e, polipeptídeo isolado BRPI0715975A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US82271506P	2006-08-17	2006-08-17
US82734806P	2006-09-28	2006-09-28
US91717807P	2007-05-10	2007-05-10
PCT/US2007/076180 WO2008022302A2 (en)	2006-08-17	2007-08-17	Immunogenic pcpa polypeptides and uses thereof

Publications (1)

Publication Number	Publication Date
BRPI0715975A2 true BRPI0715975A2 (pt)	2014-03-18

Family

ID=38942273

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0715975-7A2A BRPI0715975A2 (pt)	2006-08-17	2007-08-17	Fragmento imunogênico de pcpa, composição,recipiente, métodos de gerar anticorpos específicos para pcpa em um indivíduo, de prevenir ou reduzir portador nasal pneumocócico em um indivíduo, e de reduzir o risco de uma infecção pneumocócica em um indivíduo, e, polipeptídeo isolado

Country Status (11)

Country	Link
US (2)	US20110002962A1 (pt)
EP (2)	EP2081953A2 (pt)
JP (3)	JP2010501012A (pt)
KR (1)	KR101523108B1 (pt)
CN (2)	CN107056902A (pt)
AU (1)	AU2007285775B2 (pt)
BR (1)	BRPI0715975A2 (pt)
CA (2)	CA2660743C (pt)
IL (1)	IL197094A (pt)
MX (1)	MX2009001778A (pt)
WO (3)	WO2008022298A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6800744B1 (en)	1997-07-02	2004-10-05	Genome Therapeutics Corporation	Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US9134303B1 (en)	1998-08-25	2015-09-15	Alere Scarborough, Inc.	ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en) *	1998-09-18	2004-11-30	Binax, Inc.	Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US20110002962A1 (en) *	2006-08-17	2011-01-06	The Uab Research Foundation	Immunogenic PcpA Polypeptides and Uses Thereof
WO2008124920A1 (en) *	2007-04-12	2008-10-23	The Governors Of The University Of Alberta	Urine based detection of a disease state caused by a pneumococcal infection
CN101952728B (zh)	2008-02-01	2016-05-11	圣诺菲·帕斯图尔有限公司	用于诊断肺炎链球菌的试验
KR20110009157A (ko) *	2008-04-16	2011-01-27	글락소스미스클라인 바이오로지칼즈 에스.에이.	백신
WO2009143483A2 (en) *	2008-05-22	2009-11-26	The Board Of Regents Of The University Of Texas System	PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION
CN106008679A (zh) *	2008-12-24	2016-10-12	荷兰王国卫生福利和运动部国家公共卫生和环境研究所	修饰的肺炎链球菌溶血素(ply)多肽
JP5204036B2 (ja) *	2009-05-28	2013-06-05	旭化成株式会社	肺炎球菌の検出方法
KR20120107121A (ko) *	2009-12-22	2012-09-28	사노피 파스퇴르 리미티드	면역원성 조성물
WO2011075822A1 (en)	2009-12-22	2011-06-30	Sanofi Pasteur Limited	Immunogenic compositions and related methods
US20110262989A1 (en) *	2010-04-21	2011-10-27	Nanomr, Inc.	Isolating a target analyte from a body fluid
AU2011336366B2 (en) *	2010-12-03	2016-05-12	Sanofi Pasteur Limited	Composition for immunization against Streptococcus pneumoniae
US8603769B2 (en) *	2011-10-07	2013-12-10	Becton, Dickinson And Company	Method for direct and rapid identification of microorganisms and antimicrobial susceptibility testing from positive blood cultures
WO2013130759A1 (en)	2012-02-29	2013-09-06	Becton, Dickinson And Company	Formulations and process for isolating viable microorganism from positive blood cultures
US9107906B1 (en)	2014-10-28	2015-08-18	Adma Biologics, Inc.	Compositions and methods for the treatment of immunodeficiency
CN104306965B (zh) *	2014-10-31	2017-05-10	康希诺生物股份公司	预防肺炎链球菌感染性疾病的免疫原性组合物及制备方法
BR112018010873A2 (pt) *	2015-12-01	2019-04-30	The Procter & Gamble Company	compostos e métodos para inibir a produção de trimetilamina
JP6770805B2 (ja) *	2016-01-28	2020-10-21	旭化成株式会社	検体中の特定の細菌を検出する方法
US10738338B2 (en)	2016-10-18	2020-08-11	The Research Foundation for the State University	Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN106636149B (zh) *	2017-01-03	2019-10-25	内蒙古农业大学	斯氏副柔线虫丝氨酸/苏氨酸蛋白激酶Pj_STPK基因克隆、原核表达方法及应用
US10259865B2 (en)	2017-03-15	2019-04-16	Adma Biologics, Inc.	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110387427A (zh) *	2018-04-16	2019-10-29	马东礼	用于检测肺炎链球菌的引物组及试剂盒

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4425330A (en) *	1981-05-20	1984-01-10	Cornell Research Foundation, Inc.	Bovine mastitis vaccine and method for detecting efficacy thereof
US6027734A (en) *	1991-02-15	2000-02-22	Uab Research Foundation	Mucosal administration of pneumococcal antigens
US6592876B1 (en) *	1993-04-20	2003-07-15	Uab Research Foundation	Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5792457A (en) *	1991-05-03	1998-08-11	The Rockefeller University	Antibody recognizing endothelial cell ligand for leukocyte CR3
US5854416A (en) *	1991-11-14	1998-12-29	The United States Of America As Represented By The Department Of Health And Human Services	Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
US6312944B1 (en) *	1991-11-14	2001-11-06	The United States Of America As Represented By The Department Of Health And Human Services	Pneumococcal fimbrial protein A
US6245335B1 (en) *	1996-05-01	2001-06-12	The Rockefeller University	Choline binding proteins for anti-pneumococcal vaccines
ATE348887T1 (de) *	1996-10-31	2007-01-15	Human Genome Sciences Inc	Streptococcus pneumoniae antigene und impfstoffe
US6800744B1 (en) *	1997-07-02	2004-10-05	Genome Therapeutics Corporation	Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
IS4518A (is) *	1997-07-09	1999-01-10	Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group	Nýtt lyfjaform fyrir bóluefni
US6518412B1 (en) *	1997-09-29	2003-02-11	Jean-Louis Dasseux	Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
WO2000006737A2 (en)	1998-07-27	2000-02-10	Microbial Technics Limited	Streptococcus pneumoniae proteins and nucleic acid molecules
US6565856B1 (en) *	1998-12-08	2003-05-20	Corixa Corporation	Compounds and methods for treatment and diagnosis of chlamydial infection
AT407958B (de) *	1999-02-11	2001-07-25	Immuno Ag	Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
CA2379327A1 (en) *	1999-06-10	2000-12-21	Uab Research Foundation	Pneumococcal surface protein combination vaccine
GB0022742D0 (en) *	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
GB0107658D0 (en) *	2001-03-27	2001-05-16	Chiron Spa	Streptococcus pneumoniae
KR100886095B1 (ko)	2001-04-16	2009-02-27	와이어쓰 홀딩스 코포레이션	폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
GB0130215D0 (en) *	2001-12-18	2002-02-06	Glaxosmithkline Biolog Sa	Vaccine
AU2003226131A1 (en) *	2002-03-28	2003-10-13	Bristol-Myers Squibb Company	Novel human cell surface protein with immunoglobulin folds, bgs-19
EP2426139B1 (en) *	2002-08-27	2014-10-01	Biokine Therapeutics Ltd.	CXCR4 antagonist and use thereof
US7635487B2 (en) *	2003-04-15	2009-12-22	Intercell Ag	S. pneumoniae antigens
AU2004289295B2 (en) *	2003-11-10	2010-08-12	The Uab Research Foundation	Compositions for reducing bacterial carriage and CNS invasion and methods of using same
EP1771205B1 (en) *	2004-06-18	2016-10-26	Ambrx, Inc.	Novel antigen-binding polypeptides and their uses
JP5792920B2 (ja) *	2005-12-22	2015-10-14	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
US20110002962A1 (en) *	2006-08-17	2011-01-06	The Uab Research Foundation	Immunogenic PcpA Polypeptides and Uses Thereof
CN101952728B (zh) *	2008-02-01	2016-05-11	圣诺菲·帕斯图尔有限公司	用于诊断肺炎链球菌的试验
GB201104897D0 (en) *	2011-03-23	2011-05-04	Immunobiology Ltd	Method for the production of protein complexes and vaccine compositions comprising the same

2007
- 2007-08-17 US US12/377,446 patent/US20110002962A1/en not_active Abandoned
- 2007-08-17 JP JP2009524814A patent/JP2010501012A/ja active Pending
- 2007-08-17 CN CN201710065320.9A patent/CN107056902A/zh active Pending
- 2007-08-17 MX MX2009001778A patent/MX2009001778A/es active IP Right Grant
- 2007-08-17 JP JP2009524813A patent/JP5081243B2/ja not_active Expired - Fee Related
- 2007-08-17 WO PCT/US2007/076168 patent/WO2008022298A2/en not_active Ceased
- 2007-08-17 AU AU2007285775A patent/AU2007285775B2/en not_active Ceased
- 2007-08-17 KR KR1020097005391A patent/KR101523108B1/ko not_active Expired - Fee Related
- 2007-08-17 WO PCT/US2007/076180 patent/WO2008022302A2/en not_active Ceased
- 2007-08-17 WO PCT/US2007/076172 patent/WO2008022299A1/en not_active Ceased
- 2007-08-17 BR BRPI0715975-7A2A patent/BRPI0715975A2/pt not_active Application Discontinuation
- 2007-08-17 CN CNA2007800383929A patent/CN101573374A/zh active Pending
- 2007-08-17 CA CA2660743A patent/CA2660743C/en not_active Expired - Fee Related
- 2007-08-17 US US12/377,440 patent/US8252546B2/en not_active Expired - Fee Related
- 2007-08-17 EP EP07814208A patent/EP2081953A2/en not_active Withdrawn
- 2007-08-17 CA CA002661210A patent/CA2661210A1/en not_active Abandoned
- 2007-08-17 EP EP07814201A patent/EP2059807B1/en not_active Not-in-force
2009
- 2009-02-17 IL IL197094A patent/IL197094A/en active IP Right Grant
2013
- 2013-05-21 JP JP2013106825A patent/JP5932711B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20100227341A1 (en)	2010-09-09
WO2008022298A2 (en)	2008-02-21
CN107056902A (zh)	2017-08-18
CA2660743C (en)	2015-11-24
JP2010501012A (ja)	2010-01-14
US20110002962A1 (en)	2011-01-06
JP5932711B2 (ja)	2016-06-08
AU2007285775A1 (en)	2008-02-21
EP2081953A2 (en)	2009-07-29
CA2660743A1 (en)	2008-02-21
WO2008022302A2 (en)	2008-02-21
WO2008022302A3 (en)	2008-04-03
IL197094A (en)	2014-12-31
JP2010501078A (ja)	2010-01-14
CN101573374A (zh)	2009-11-04
KR101523108B1 (ko)	2015-05-26
MX2009001778A (es)	2009-05-22
US8252546B2 (en)	2012-08-28
EP2059807B1 (en)	2013-02-20
WO2008022299A1 (en)	2008-02-21
AU2007285775B2 (en)	2011-03-03
JP5081243B2 (ja)	2012-11-28
JP2013155205A (ja)	2013-08-15
IL197094A0 (en)	2011-08-01
EP2059807A1 (en)	2009-05-20
EP2059807A4 (en)	2010-01-27
WO2008022298A3 (en)	2008-04-03
CA2661210A1 (en)	2008-02-21
KR20090071551A (ko)	2009-07-01

Legal Events

Date	Code	Title	Description
2016-05-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-03-20	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-09	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-01-29	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-08-13	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements

Publication	Publication Date	Title
CL2007000478A1 (es)	2008-03-14	Anticuerpo humano o humanizado o fragmento funcional del mismo especifico para linfopoyetina estromal timica, tslp; polinucleotido que lo codifica; celula huesped que lo comprende; composicion farmaceutica que comprende al anticuerpo; y metodo para t
BRPI0813311A2 (pt)	2014-12-23	Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
BRPI0919876A2 (pt)	2015-08-18	Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
BRPI0907663A2 (pt)	2015-07-21	''composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições.
BRPI0915986A2 (pt)	2015-11-03	composição, métodos para tratar uma condição, para retardar o início de uma condição, para reduzir o risco em um indivíduo de adquirir uma condição e para alterar a expressão de um ou mais genes em um indivíduo
BR112012018951A2 (pt)	2017-06-27	composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BRPI1009381A2 (pt)	2016-06-21	compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
CL2014000400A1 (es)	2014-08-29	Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
BRPI0908503A2 (pt)	2015-09-29	partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
ZA201001789B (en)	2011-12-28	Composition and methods for use for antibodies against sclerostin
BR112012018947A8 (pt)	2017-12-19	composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BRPI0911681A2 (pt)	2017-05-02	composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula
BRPI0905737A2 (pt)	2017-03-01	"conjunto de um recipiente e um fecho, fecho e recipiente"
IL204542A (en)	2016-03-31	Unique monoclonal antibodies for protofibrillary form of cellulose-amyloid protein, methods and uses thereof
DK2282994T3 (da)	2013-09-30	3-aminocarbazolforbindelse, farmaceutisk sammensætning indeholdende forbindelsen samt fremstillingsmetode derfor
BRPI0813645A2 (pt)	2014-12-30	Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
CL2007002649A1 (es)	2008-04-11	Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes.
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
BRPI0819299A2 (pt)	2014-10-07	Uso de composição, e, composição contendo proteína
BRPI0818544A2 (pt)	2015-06-16	Processo para tratamento de uma combinação contendo organossilano, composição e uso de uma resina orgânica.
HUS1800034I1 (hu)	2018-09-28	Anti-FGF23 ellenanyag és anti-FGF23 ellenanyagot tartalmazó gyógyászati készítmény
BRPI0917728A2 (pt)	2016-02-16	composição, uso da composição, e, método de prevenção da formação de espuma em uma composição
PL2303455T3 (pl)	2017-01-31	Kompozycja katalizatora i sposób, w którym stosuje się kompozycję katalizatora do hydrokonwersji surowca - węglowodorów ciężkich
BRPI0811059A2 (pt)	2017-05-09	combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
EA201200484A1 (ru)	2012-12-28	Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином